STOCK TITAN

ANRO ownership: Commodore files 13G for 3.19M shares, 9.8%

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Alto Neuroscience (ANRO): Schedule 13G filed reporting a passive stake by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz. The filers beneficially own 3,190,267 shares of common stock, representing 9.8% of the class.

The position includes 1,653,913 common shares and 1,536,354 shares issuable upon exercise of a pre-funded warrant, subject to a Beneficial Ownership Limitation. Ownership percentages are based on 30,908,892 shares outstanding as of October 20, 2025, plus the shares underlying the pre-funded warrant. The filers report shared voting and dispositive power over 3,190,267 shares and certify the securities were not acquired to change or influence control.

Positive

  • None.

Negative

  • None.

Insights

Passive 9.8% stake, partly via pre-funded warrant.

Commodore Capital and affiliates disclosed beneficial ownership of 3,190,267 Alto Neuroscience shares, equal to 9.8%. The stake comprises 1,653,913 common shares plus 1,536,354 shares issuable from a pre-funded warrant, constrained by a Beneficial Ownership Limitation.

The filing cites an outstanding share count of 30,908,892 as of October 20, 2025, adding the warrant shares for the percentage calculation. The group reports shared voting and dispositive power and filed on a passive basis consistent with Schedule 13G certification.

Key variables include any changes to the outstanding share count and warrant exercises; actual impact depends on holder decisions and subsequent disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Managing Partner
Date:10/27/2025
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:10/27/2025
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:10/27/2025
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:10/27/2025
Exhibit Information

Exhibit 1: Joint Filing Agreement

FAQ

What stake in ANRO did Commodore Capital report?

They reported beneficial ownership of 3,190,267 shares, or 9.8% of Alto Neuroscience’s common stock.

How is the 3,190,267-share position in ANRO composed?

It includes 1,653,913 common shares and 1,536,354 shares issuable upon exercise of a pre-funded warrant.

What share count was used to calculate ANRO ownership percentage?

Ownership is based on 30,908,892 shares outstanding as of October 20, 2025, plus the warrant shares.

Do the filers have voting and dispositive power over the ANRO shares?

Yes. They report shared voting and dispositive power over 3,190,267 shares and no sole power.

Is this a passive or activist filing for ANRO?

It is a Schedule 13G with a certification indicating the securities were not acquired to change or influence control.

Who are the reporting persons in this ANRO Schedule 13G?

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz.
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

ANRO Latest News

ANRO Latest SEC Filings

ANRO Stock Data

610.76M
26.80M
7.48%
64.06%
6.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW